Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Alzheimer’s biotech Korsana to go public via reverse merger

 April 2, 2026

Pharmaphorum

By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer’s.

M&A / DealsNeuroscienceRead full story

Post navigation

Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets →
← Merck KGaA acquires JSR chromatography business

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com